

Cite this: *Chem. Sci.*, 2022, 13, 13475

All publication charges for this article have been paid for by the Royal Society of Chemistry

Discovery of pentaene polyols by the activation of an enediyne gene cluster: biosynthetic implications for 9-membered enediyne core structures†

Jian Pan,^a Qingwen Tan,^a Saibin Zhu,^a Xiaohui Yan,^d Yu Li,^a Zhoukang Zhuang,^a Xiangcheng Zhu,^{ac} Yanwen Duan^{abc} and Yong Huang^{id *ab}

The identification and characterization of enediyne polyketide synthases (PKSEs) revealed that PKSE-bound polyene is a common intermediate, while its subsequent tailoring steps to enediyne cores remain obscure. Herein, we report pentaene polyols 5–7 and cinnamic acid derivatives 8 and 9 biosynthesized from an activated enediyne biosynthetic gene cluster in *Streptomyces* sp. CB02130. The C-1027 *pksE* could partially complement production of these polyene polyols in a CB02130 mutant where the native *pksE* is inactivated. The yields of 5–7 were improved by increasing the cellular pool of L-Phe through either gene inactivation of a prephenate dehydrogenase WlsPDH or supplementation of L-Phe. A flexible ammonia lyase WlsC4 is responsible for biosynthesis of 8 and 9 from L-Phe. The co-localization of WlsPDH and PKSE gene cassette supports their close evolutionary relationships and an enediyne genome mining strategy using WlsPDH. These findings not only provide a facile approach to activate silent enediyne BGCs, but suggest that a polyene epoxide intermediate may be formed for construction of 9-membered enediyne macrocycles.

Received 5th August 2022
Accepted 28th October 2022

DOI: 10.1039/d2sc04379c

rsc.li/chemical-science

Introduction

Enediyne natural products are characterized by the unique conjugation of two acetylenic groups to a double bond within a 9- or 10-membered carbocycle (Fig. 1 and S1†).^{1–4} The last two decades have witnessed deciphering the unique biosynthetic logic of enediyne natural products, including the identification of their biosynthetic gene clusters (BGCs),^{5–12} the discovery and characterization of highly reducing iterative polyketide synthases (PKSEs) for enediyne assembly,^{13–20} as well as novel enzymology to construct peripheral moieties into enediyne architectures.^{21–26} However, the biosynthesis of enediyne cores has been a topic of great interest and remains largely a mystery. The carbon skeleton of enediyne cores is formed from iterative condensation of malonyl-CoA catalyzed by PKSEs, leading to the isolation of several polyenes 1–4,^{13–16,18–20} among which β -hydroxy acid 4 or its

PKSE-bound analog was considered as the common intermediate for 9- or 10-enediayne core biosynthesis.^{13,16,20} However, further tailoring steps for enediayne construction and how the 9- or 10-membered rings diverge remain unknown. Some underlying reasons may include that (1) the functions of many conserved




Fig. 1 Proposed biosynthesis of enediyne cores. (A) Representative 9-membered enediynes. (B) Biosynthesis of PKSE-catalyzed formation of polyenes from acetate.

^aXiangya International Academy of Translational Medicine, Central South University, Changsha, Hunan 410013, China. E-mail: jonghuang@csu.edu.cn

^bHunan Engineering Research Center of Combinatorial Biosynthesis and Natural Product Drug Discovery, Changsha, Hunan 410205, China

^cNational Engineering Research Center of Combinatorial Biosynthesis for Drug Discovery, Changsha, Hunan 410205, China

^dState Key Laboratory of Natural and Biomimetic Drugs, Peking University, Beijing, China, State Key Laboratory of Component-Based Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, China

† Electronic supplementary information (ESI) available: Full experimental details and procedures, Fig. S1–S61; Tables S1–S36. See DOI: <https://doi.org/10.1039/d2sc04379c>



genes for enediyne biosynthesis are unknown and (2) only a few metabolites, *e.g.* 1–4, related to enediyne core processing were discovered.

We and our colleagues recently reported *PKSE* gene cassette-based genome mining approaches to discover enediyne producers, leading to the isolation of new anthraquinone-fused enediynes and several high-yield producers of C-1027.^{27–30} These studies not only show wide-spread enediyne BGCs and their huge biosynthetic potential, but highlight significant challenges to activate silent enediyne BGCs and harness novel chemistry, including intermediate steps towards enediyne core biosynthesis.

Here, we report the activation of a putative Wuliangshan (*wls*) enediyne BGC in *Streptomyces* sp. CB02130 and the discovery of three novel pentaene polyols 5–7 and cinnamic acid derivatives 8 and 9. Their biosynthetic study suggests that 5–7 are likely shunt metabolites during the construction of 9-membered enediynes, which support epoxidation of the PKSE-tethered polyene intermediate during the biosynthesis of 9-membered enediynes.

Results and discussion

Bioinformatics analysis revealed a subclass of putative enediyne BGCs

Bioinformatic analysis revealed a sub-cluster of putative enediyne BGCs with a conserved regulatory network with

neocarzinostatin (Fig. 2 and S2†).⁷ *S. sp.* CB02130 was prioritized as a prototype for this sub-family since it could produce the heptaene metabolite 1, while no enediyne natural products could be identified. Heterologous expression of *WlsPKSE* and a type II thioesterase *WlsE10* in *Escherichia coli* also accumulated 1, which further supports the operation of previously reported enediyne PKS chemistry in CB02130 (Fig. S3 and Table S2†).

Discovery of 5–9 from an activated *wls* BGC

Since manipulation of pathway-situated regulators could improve the yield of C-1027,^{32,33} we systematically inactivated putative negative regulators in *wls* BGC by gene replacement of *wlsR2* and *wlsR3* using a thiostrepton-resistance gene. An extra copy of putative positive regulators, including *wlsR1*, *wlsR5*, *wlsR6*, and *wlsR7*, was also individually introduced into CB02130 through site-specific integration (Fig. S4†).³⁴ When we inactivated *wlsR3* encoding a TetR regulator, a series of metabolites 5–9 were produced, while $\Delta wlsR2$ and mutants overexpressing *wlsR1*, *wlsR5*, *wlsR6*, and *wlsR7* had no obvious metabolite overproduction (Fig. 2B, panel II; S5, S9†). Introduction of *wlsR3* to $\Delta wlsR3$ mutant restored its phenotype to the wild-type strain (Fig. 2B, panel III). Interestingly, deletion of *wlsE* and *wlsE10* in $\Delta wlsR3$ only abolished the production of 5–7. Inactivation of *wlsC4* encoding a 4-methylideneimidazole-5-one-dependent ammonia lyase abolished the production of 8




Fig. 2 Production and structure elucidation of 5–9 from *S. sp.* CB02130. (A) The high sequence similarity between *wls* and neocarzinostatin BGCs. (B) Activation of *wls* BGC to produce 5–9 and identification of genes for their biosynthesis. (C) Structure elucidation of 5–9.



and **9** (Fig. 2B, panels VI). The above data suggest the activation of *wls* BGC in $\Delta wlsR3$.

Compounds **5–7** are likely related to enediyne core biosynthesis, but the low titer hindered their isolation. Further analysis of *wls* BGC revealed two potential chorismate-related pathways: *WlsD* and *WlsG* share high sequence identity with *SgcD* and *SgcG* for the biosynthesis of benzoxazolinone from chorismate in C-1027,³¹ while *wlsOrf3* and *wlsPDH* encode putative chorismatase and prephenate dehydrogenase (PDH), respectively. *WlsOrf3* and *wlsPDH*, along with *wlsOrf30* predicted to encode a 2-hydroxyacyl-CoA lyase, are not present in the known enediyne BGCs (Fig. S2†). We therefore deleted *wlsOrf3*, *wlsOrf30*, and *wlsPDH* in $\Delta wlsR3$, respectively, to investigate their roles in **5–9** biosynthesis (Fig. 2B, panels VII–X). No new metabolites and obvious yield change of **5–9** were observed in $\Delta wlsORF3/\Delta wlsR3$ and $\Delta wlsORF30/\Delta wlsR3$; in contrast, the yields of **5–7** increased by about 8-fold in $\Delta wlsPDH/\Delta wlsR3$, while gene replacement of *wlsPDH* in CB02130 wild-type had no obvious changes (Fig. 2B, panel XI). Gene inactivation of *wlsR3* or *wlsR3* and *wlsPDH* also led to significant overproduction of heptaene **1**, while further overexpression of putative positive regulators *wlsR1* and *wlsR6* under the control of *ermEp** in $\Delta wlsR3$ had no effects towards the production of **1** and **5–7** (Fig. S14 and S15†).

Scaled-up fermentation of $\Delta wlsR3$ or $\Delta wlsPDH/\Delta wlsR3$ mutants thus led to the isolation of **8** and **9**, or **5–7**, respectively. Compound **5** was isolated as a colorless powder that was analyzed for the molecular formula $C_{15}H_{22}NaO_4$, by HR-ESI-MS (m/z 289.1403 [M + Na]⁺, calcd 289.1416) (Fig. S6†). It contains five degrees of unsaturation, consistent with a conjugated pentaene structure with characteristic UV/Vis absorption at λ_{max} 312.2, 330.2, and 348.2 nm. Analyses of 1D and 2D NMR spectra of **5** revealed that it contains one terminal methyl as a doublet at λ 1.1 ($J = 6.6$ Hz, H15) and one terminal hydroxymethyl at λ 3.49 (2H, m, H1), three oxymethine protons [3.62 (1H, t, $J = 6.6$), H14; 3.90 (1H, m), H13; 4.17 (1H, m), H2], two *trans* olefinic protons [5.74 (1H, dd, $J = 15, 3.0$ Hz), H12; 5.73 (1H, dd, $J = 15, 2.4$ Hz), H3], and eight overlapping olefinic protons at λ 6.27–6.33 (m, H5–H10) (Table S4 and Fig. S16–S26†). HSQC and HMBC experiments showed that these proton signals correlated with their corresponding ¹³C NMR bands and established their connections. The geometry of the remaining three double bonds is likely in the *E* configuration, since (1) **5** is the iterative acting PKSE product and (2) the overlapping signals of H5–H10 would suggest a pseudo-centrosymmetric structure, similar to all *trans* configurations of **1–4**. Therefore, the planar structure of **5** was identified as (3*E*, 5*E*, 7*E*, 9*E*, 11*E*)-pentaene-1, 2, 13, 14-tetraol.

Compound **6** was likely a diastereoisomer of **5**, since both compounds had identical HR-ESI-MS and similar NMR data (Table S4 and Fig. S27–S39†). Compound **7** was isolated as a colorless powder with an almost identical UV/Vis spectrum to **5**, suggesting a similar molecular structure. The difference of **7** is that it contains two extra hydroxymethyl groups [3.59 (2H, br m), H1'; 3.48 (2H, m), H3'] and one oxymethine proton at λ 3.65 (1H, m, H2'), corresponding to a three-carbon glycerol unit (Fig. S40–S53†). HMBC correlations from H-1 to C-1', H-2 to C-3',

as well as H-1' to C-3' and H-3' to C-1' established the connection of the glycerol unit to the pentaene skeleton of **7**.

The 13,14-diol in **5/6/7** was assigned with an anti-configuration, due to the relatively large ³ $J_{H,H}$ constants (6.6 Hz) and the presence of NOE between H-15/H-13 and H-12/H-14 and the absence of NOE between H-12/H-15.³⁹ The characteristic electronic circular dichroism of **5** and **6** also suggested that they are diastereoisomers (Fig. S7†). However, **5** had no optical rotation when measured in methanol, suggesting a pseudo mesomeric structure. Several highly symmetric polyene polyols with a tetraene unit flanked by diols were isolated, while their optical rotation ranged from -2 to -15 .⁴⁰ In contrast, **6** exhibits an optical rotation of $[\alpha]_D^{25} +149$ (c 0.04, MeOH) and less signal overlapping in both its ¹H and ¹³C spectra, indicating rather different stereochemistry. Taken together, the relative stereochemistry of **5–7** is shown in Fig. 2B. The structures of **8** and **9** were determined by their corresponding 1D and 2D NMR and HR-ESI-MS, which are the known cinnamic acid derivatives (Fig. S6 and S54–S61†).

Since PKSE genes belonging to 9-membered enediynes could cross-complement C-1027 or neocarzinostatin production when the native *pksE* gene was inactivated,¹³ we therefore overexpressed *wlsE10* and *pksE* for C-1027 biosynthesis from *Streptomyces* sp. CB02366 in the $\Delta wlsE/\Delta wlsR3$ mutant (Fig. 3).³⁰ Both mutants overexpressing *pksE*_{CB02366} and *wlsE* could produce **1** and partially restored the production of **5–7** in the *wlsE* null mutant, suggesting the operation of enediyne PKS chemistry and interaction of C-1027 PKSE with accessory enzymes in CB02130.

Since the 1, 2-diol functionality is present in many known 9-membered enediyne natural products, epoxide hydrolases including *SgcF* and *NcsF2* from C-1027 or neocarzinostatin BGCs were proposed for the hydrolysis of epoxide intermediates.^{35–37} To study the role of *WlsF*, a close homolog of




Fig. 3 Cross-complementation of the PKSE function in the $\Delta wlsE/\Delta wlsR3$ mutant by *WlsE* and PKSE for C-1027 biosynthesis from *Streptomyces* sp. CB02366. (A) The production of pentaene polyols **5–7**. (B) The production of heptane (**1**) was observed in the complementation mutants (panels III and IV).



SgcF and NcsF2 for the formation of vicinal diols in 5–7, it was inactivated in $\Delta wlsR3$. The production of 5–7 was unchanged in the resulting mutant (Fig. 2B, panel XII). We next inactivated *wlsORF8* and *wlsORF24* encoding putative monooxygenases with high sequence similarity to SpoT4 and SpoORF18 in sporolides BGC,¹⁰ as well as putative oxidoreductase genes *wlsL* and *wlsE9*, and cytochrome P450 monooxygenase gene *wlsE7* in the $\Delta wlsR3$ mutant, while the production of 5–7 seemed unchanged in the resulting mutant strains $\Delta wlsORF8/\Delta wlsR3$, $\Delta wlsORF24/\Delta wlsR3$, $\Delta wlsL/\Delta wlsR3$, $\Delta wlsE7/\Delta wlsR3$, and $\Delta wlsE9/\Delta wlsR3$ (Fig. S13†).

Characterization of WlsC4 as an amino lysase

Both **8** and **9** disappeared when *wlsC4* was inactivated in $\Delta wlsR3$ (Fig. 2B, panel VI). This suggests that **9** was likely a product of WlsC4, while further O-methylation of **8** may yield **9**. Bioinformatics analysis showed that WlsC4 shares high sequence similarity to several L-Tyr or L-Phe ammonia mutases or lysases, including SgcC4 (80.45% amino acid sequence identity) known as amino mutase that converts L-Tyr into (S)- β -tyrosine.^{41–43} However, *in vitro* assay confirmed that purified WlsC4 from heterologous expression in *E. coli* utilized both L-Tyr or L-Phe as substrates to produce 4-hydroxyl cinnamic acid or cinnamic acid, while it prefers L-Tyr (Fig. 4). To decipher whether L-Tyr or L-Phe was the substrate for WlsC4 *in vivo*, both compounds were individually added to the production medium of the $\Delta wlsR3$ mutant as a sole nitrogen source (Fig. S11†). Surprisingly, 5–9 could only be produced with the exogenous L-Phe, while the production of heptaene **1** was comparable when either L-Tyr or L-Phe was used. These data suggest that L-Phe may be the genuine substrate for biosynthesis of cinnamic acid derivatives **8** and **9**, while the cellular concentration of L-Phe is important to regulate the production of pentaene polyols 5–7. In addition, supplementation of L-Phe (6 mM) to the original production medium significantly increased the yields of 5–7 in $\Delta wlsR3$, even comparable to those in $\Delta wlsPDH/\Delta wlsR3$ (Fig. S12†). WlsPDH shares 30.69% sequence identity with characterized prephenate dehydrogenase MtPDH from *Mycobacterium tuberculosis* H37Rv and it can oxidatively decarboxylate prephenate derived from chorismate to 4-hydroxyphenylpyruvate, followed by its conversion into L-Tyr by tyrosine aminotransferase. Gene inactivation of *wlsPDH* likely increased the cellular L-Phe concentration by removing the branch point to L-Tyr from chorismate, since it can oxidatively decarboxylate prephenate derived from chorismate, which thus led to enhanced pentaene polyol production (Fig. 2B, panel X).

In silico genome mining of enediynes BGCs containing wlsPDH homologs

We next studied the distribution of WlsPDH homologs in GenBank and its evolutionary relationship with enediynes BGCs (Fig. 5). Using WlsPDH as an *in silico* probe, a GenBank BlastP search resulted in 67 homologous PDH proteins clustered with putative enediynes BGCs (Table S5†). Phylogenetic analysis revealed that WlsPDH and homologous proteins are from actinomycetes, and they are clustered in one clade clearly separated




Fig. 4 Characterization of WlsC4 as an L-Tyr and L-Phe ammonia lyase *in vitro*.

from the known PDHs or arogenate dehydrogenases. These 67 putative enediynes BGCs were then winnowed into 31 representative BGCs by a PKSE similarity threshold of 93.86%, which resulted in an enediynes genome neighborhood network (Tables S6–S36†). The newly discovered enediynes BGCs likely all belong to the 9-membered enediynes family, since they contain the 9-membered enediynes conserved genes, including *E2*, *E7–E9*, *E11*, as well as *M* and *J*, while all of them contain one PDH.

Proposed pathway for putative enediynes natural product biosynthesis in *wls* BGC

Gene inactivation of *wlsR3* led to activation of *wls* BGC in *S. sp.* CB02130 and the production of polyene polyol 5–7, suggesting a common polyene epoxide precursor for the 9-membered enediynes core (Fig. 6): a hydrogen atom may be abstracted from the terminal methyl group of the polyene intermediate **10** to yield resonance and generate **11**,^{19,20,38} followed by epoxidation of C15–C16 to produce **12** and then ring closure of C4–C15 in a site-specific fashion and cleavage of oxygenated C16. In contrast, quenching of the allylic radical **12** by a hydroxyl radical, followed by nucleophilic addition of H₂O or glycerol to its terminal epoxide and hydrolysis mediated by WlsE10 and






Fig. 5 (A) Phylogenetic analysis of 67 PKSE co-localized with putative prephenate dehydrogenases mined from GenBank using WisPDH as a probe. PDHs from streptomycetes are labeled in blue, while these from other actinomycetes are labeled in purple. Previously characterized proteins are labeled with a black circle with their preferred PDH or ADH activity. (B) The genome neighborhood network analysis of 31 putative enediyne BGCs, along with C-1027, neocarzinostatin, and *wls* BGCs. The enediyne BGC sub-cluster contains PKSE gene cassette (*i.e.*, *E3*, *E4*, *E5*, *E*, *E10*) and the seven additional conserved genes (*i.e.* *E2*, *E7*, *E8*, *E9*, *E11*, *M*, *J*) of 9-membered enediynes. The analysis was displayed with an *E*-value threshold of 10^{-6} .

subsequent decarboxylation would afford 5–7. Compared to 1–4, the production of these pentaene polyols suggests accessory enzyme-mediated oxidation for 9-membered enediyne core biosynthesis. Alternative mechanisms for the construction of the enediyne core without the epoxide formation, including

carbocation or electrocyclic chemistry, may also be possible. These data support the proposal that 9- and 10-membered enediyne biosynthesis diverges in post-PKS steps.¹⁷ We also envision the converged biosynthesis of a putative 9-membered enediyne natural product from the enediyne core and




Fig. 6 A proposed biosynthetic mechanism for potential 9-membered enediyne natural products in *S. sp.* CB02130.



a cinnamic acid derivative *via* chorismate metabolism in CB02130. In addition, the co-localization of homologous PDHs in these 31 BGCs suggests it as a convenient probe to discover potential enediyne BGCs, while their role in coordinating chorismate metabolism and enediyne biosynthesis needs further study.

Conclusion

Biosynthetic study of enediyne natural products continually provides new natural products and new enzymology.^{3,4,22} Here, we have reported the isolation and structure elucidation of 5–9 from the activated *wls* enediyne BGC by gene inactivation of a negative transcriptional regulator *wlsR3*. The correlation of the polyene polyols 5–7 with enediyne core biosynthesis was established by genetic complementation of a *wlsE/wlsR3* mutant using *PKSE* from the C-1027 biosynthetic pathway. We further discovered that an ammonia lyase *WlsC4* is involved in the formation of 8 and 9, and proposed that *WlsPDH* could be used as an *in silico* probe to discover enediyne BGCs. Although we were unable to obtain genuine enediynes from *S. sp.* CB02130, the isolation and initial biosynthetic studies of 5–9 is one step forward to understanding how nature builds 9-membered enediyne chromophores, especially in this specific sub-class.

Data availability

Experimental procedures and characterization for all new compounds are available in the ESI.†

Author contributions

Conceptualization, Y. H., Y. D. and J. P.; methodology, J. P., Q. T., S. Z., and Y. L.; formal analysis, J. P., Q. T., and Y. H.; resources, X. Y., Z. Z., X. Z.; writing – original draft, Y. H. and J. P.; writing – review and editing, Y. H. and J. P. with input from all authors. Funding acquisition, Y. H., Y. D., J. P., X. Y.

Conflicts of interest

There are no conflicts to declare.

Acknowledgements

This work was supported in parts by NSFC grants 82173688 (Y. H.) and 81872779 (X. Y.), the Science and Technology Innovation Program of Hunan Province (2021RC4067), and Hunan Provincial Natural Science Foundation of China (2021JJ30791) (Y. H.), the Chinese Ministry of Education 111 Project (BP0820034) (to Y. D.), the State Key Laboratory of Natural and Biomimetic Drugs (No. K202116 to X. Y.), the Hunan Provincial Innovation Foundation for Postgraduate and the Fundamental Research Funds for the Central Universities of Central South University (CSU) 2020zzts247 (to J. P.). We thank the Center for Advanced Research in CSU for NMR experiments.

References

- 1 K. C. Nicolaou, A. L. Smith and E. W. Yue, *Proc. Natl. Acad. Sci.*, 1993, **90**, 5881–5888.
- 2 U. Galm, M. H. Hager, S. G. Van Lanen, J. Ju, J. S. Thorson and B. Shen, *Chem. Biol.*, 2005, **105**, 739–758.
- 3 B. Shen, Hindra, X. Yan, T. Huang, H. Ge, D. Yang, Q. Teng, J. D. Rudolf and J. R. Lohman, *Bioorg. Med. Chem. Lett.*, 2015, **25**, 9–15.
- 4 X. Yan, *Nat. Prod. Rep.*, 2022, **39**, 703–728.
- 5 W. Liu, S. D. Christenson, S. Standage and B. Shen, *Science*, 2002, **297**, 1170–1173.
- 6 J. Ahlert, E. Shepard, N. Lomovskaya, E. Zazopoulos, A. Staffa, B. O. Bachmann, K. Huang, L. Fonstein, A. Czisny, R. E. Whitwam, C. M. Farnet and J. S. Thorson, *Science*, 2002, **297**, 1173–1176.
- 7 W. Liu, K. Nonaka, L. Nie, J. Zhang, S. D. Christenson, J. Bae, S. G. Van Lanen, E. Zazopoulos, C. M. Farnet, C. F. Yang and B. Shen, *Chem. Biol.*, 2005, **12**, 293–302.
- 8 S. G. Van Lanen, T. J. Oh, W. Liu, E. Wendt-Pienkowski and B. Shen, *J. Am. Chem. Soc.*, 2007, **129**, 13082–13094.
- 9 Q. Gao and J. S. Thorson, *FEMS Microbiol. Lett.*, 2008, **282**, 105–114.
- 10 A. L. Lane, S. J. Nam, T. Fukuda, K. Yamanaka, C. A. Kauffman, P. R. Jensen, W. Fenical and B. S. Moore, *J. Am. Chem. Soc.*, 2013, **135**, 4171–4174.
- 11 S. Y. Ma, Y. S. Xiao, B. Zhang, F. L. Shao, Z. K. Guo, J. J. Zhang, R. H. Jiao, Y. Sun, Q. Xu and R. X. Tan, *Org. Lett.*, 2017, **19**, 6208–6211.
- 12 J. R. Lohman, S. X. Huang, G. P. Horsman, P. E. Dilfer, T. Huang, Y. Chen, E. Wendt-Pienkowski and B. Shen, *Mol. Biosyst.*, 2013, **9**, 478–491.
- 13 J. Zhang, S. G. Van Lanen, J. Ju, W. Liu, P. C. Dorrestein, W. Li, N. L. Kelleher and B. Shen, *Proc. Natl. Acad. Sci.*, 2008, **105**, 1460–1465.
- 14 R. Kong, L. P. Goh, C. W. Liew, Q. S. Ho, E. Murugan, B. Li, K. Tang and Z. X. Liang, *J. Am. Chem. Soc.*, 2008, **130**, 8142–8143.
- 15 H. Sun, R. Kong, D. Zhu, M. Lu, Q. Ji, C. W. Liew, J. Lescar, G. Zhong and Z. X. Liang, *Chem. Commun.*, 2009, 7399–7401.
- 16 K. Belecki, J. M. Crawford and C. A. Townsend, *J. Am. Chem. Soc.*, 2009, **131**, 12564–12566.
- 17 G. P. Horsman, Y. Chen, J. S. Thorson and B. Shen, *Proc. Natl. Acad. Sci.*, 2010, **107**, 11331–11335.
- 18 X. Chen, Z. F. Guo, P. M. Lai, K. H. Sze and Z. Guo, *Angew. Chem. Int. Ed.*, 2010, **49**, 7926–7928.
- 19 K. Belecki and C. A. Townsend, *Angew. Chem., Int. Ed.*, 2012, **51**, 11316–11319.
- 20 K. Belecki and C. A. Townsend, *J. Am. Chem. Soc.*, 2013, **135**, 14339–14348.
- 21 S. G. Van Lanen and B. Shen, *Curr. Top. Med. Chem.*, 2008, **8**, 448–459.
- 22 Z. X. Liang, *Nat. Prod. Rep.*, 2010, **27**, 499–528.
- 23 X. Yan, J. J. Chen, A. Adhikari, C. N. Teijaro, H. Ge, I. Crnovcic, C. Y. Chang, T. Annaval, D. Yang, C. Rader and B. Shen, *Org. Lett.*, 2018, **20**, 5918–5921.



- 24 D. R. Cohen and C. A. Townsend, *Nat. Chem.*, 2018, **10**, 231–236.
- 25 D. R. Cohen and C. A. Townsend, *Angew. Chem. Int. Ed.*, 2018, **57**, 5650–5654.
- 26 G. L. Ma, H. T. Tran, Z. J. Low, H. Candra, L. M. Pang, Q. W. Cheang, M. Fang and Z. X. Liang, *J. Am. Chem. Soc.*, 2021, **143**, 11500–11509.
- 27 X. Yan, H. Ge, T. Huang, Hindra, D. Yang, Q. Teng, I. Crnovčić, X. Li, J. D. Rudolf, J. R. Lohman, Y. Gansemans, X. Zhu, Y. Huang, L. X. Zhao, Y. Jiang, F. Van Nieuwerburgh, C. Rader, Y. Duan and B. Shen, *mBio*, 2016, **7**, e02104–e02116.
- 28 X. Yan, J. J. Adhikari A, D. Yang, I. Crnovcic, N. Wang, C. Y. Chang, C. Rader and S. B. Chen, *Org. Lett.*, 2017, **19**, 6192–6195.
- 29 Z. Wang, Z. Wen, L. Liu, X. Zhu, B. Shen, X. Yan, Y. Duan and Y. Huang, *J. Nat. Prod.*, 2019, **82**, 2483–2488.
- 30 X. Yan, Hindra, H. Ge, D. Yang, T. Huang, I. Crnovcic, C. Y. Chang, S. M. Fang, T. Annaval, X. Zhu, Y. Huang, L. X. Zhao, Y. Jiang, Y. Duan and B. Shen, *J. Nat. Prod.*, 2018, **81**, 594–599.
- 31 S. G. Van Lanen, S. Lin and B. Shen, *Proc. Natl. Acad. Sci. U. S. A.*, 2008, **105**, 494–499.
- 32 Y. Chen, M. Yin, G. P. Horsman and B. Shen, *J. Nat. Prod.*, 2011, **74**, 420–424.
- 33 Y. Chen, M. Yin, G. P. Horsman, S. Huang and B. Shen, *J. Antibiot.*, 2010, **63**, 482–485.
- 34 M. Bierman, R. Logan, K. O'Brien, E. T. Seno, R. N. Rao and B. E. Schoner, *Gene*, 1992, **116**, 43–49.
- 35 S. Lin, G. P. Horsman, Y. Chen, W. Li and B. Shen, *J. Am. Chem. Soc.*, 2009, **131**, 16410–16417.
- 36 S. Lin, G. P. Horsman and B. Shen, *Org. Lett.*, 2010, **12**, 3816–3819.
- 37 G. P. Horsman, A. Lechner, Y. Ohnishi, B. S. Moore and B. Shen, *Biochemistry*, 2013, **52**, 5217–5224.
- 38 H. M. Ge, T. Huang, J. D. Rudolf, J. R. Lohman, S. X. Huang, X. Guo and B. Shen, *Org. Lett.*, 2014, **16**, 3958–3961.
- 39 N. Matsumori, D. Kaneno, M. Murata, H. Nakamura and K. Tachibana, *J. Org. Chem.*, 1999, **64**, 866–876.
- 40 M. Bae, H. Kim, Y. Shin, B. Y. Kim, S. K. Lee, K. B. Oh, J. Shin and D. C. Oh, *Mar. drugs*, 2013, **11**, 2882–2893.
- 41 L. Xiang and B. S. Moore, *J. Biol. Chem.*, 2002, **277**, 32505–32509.
- 42 S. D. Christenson, W. Liu, M. D. Toney and B. Shen, *J. Am. Chem. Soc.*, 2003, **125**, 6062–6063.
- 43 S. D. Christenson, W. Wu, M. A. Spies, B. Shen and M. D. Toney, *Biochemistry*, 2003, **42**, 12708–12718.

